Latest research on Raloxifene

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. [PubChem]

Latest findings

These include gonadotropin releasing hormone (GnRH) analogues such as buserelin and, Goserelin, selective estrogen receptor modulators (SERM) such as Raloxifene, selective progesterone receptor modulators (SPRM) such as ulipristal, and progesterone antagonists such as mifepristone [18–21]. [source, 2016]
Raloxifene was the first SERM approved as a treatment of post-menopausal osteoporosis [25]. [source, 2016]
We have previously reported that Raloxifene has anti-arthritic and bone-protective properties in an experimental model of post-menopausal RA–CIA in ovariectomised (OVX) mice [26, 27]. [source, 2016]
We previously reported that the second-generation SERM Raloxifene inhibits arthritis and bone loss in CIA, which after prophylactic treatment was associated with decreased serum levels of IL-6 and reduced spleen TNF mRNA levels [26]. [source, 2016]
Furthermoere, Raloxifene inhibited androgen-independent PC growth in 5 (28 %) of 13 patients [13]. [source, 2015]
In the present study, we conducted a prospective randomized clinical phase IIA trial to investigate the effects of SERMs (toremifene and Raloxifene) when added to ADT in treatment-naïve bone metastatic PC. [source, 2015]
Eligible patients were randomly allocated in a 1:1:1 fashion to receive ADT alone, toremifene plus ADT (TOPADT) or Raloxifene plus ADT (RAPADT). [source, 2015]
Several recent studies have also investigated the therapeutic potential of the SERM Raloxifene in schizophrenia. [source, 2015]
In a 12 week double-blind, placebo-controlled study, orally administered Raloxifene improved probabilistic association learning and significantly increased fMRI blood Oxygen level-dependent (BOLD) activity in the hippocampus and parahippocampal gyrus relative to placebo, in male and female schizophrenic patients (Kindler et al., 2015). [source, 2015]
In a subsequent study by the same group, Raloxifene, administered orally, improved memory and attention/processing speeds in male and female schizophrenic patients, compared to placebo (Weickert et al., 2015). [source, 2015]